15% off all orders — use code PEPTA15

Research Use Only — Not for Human Consumption. This compound is sold exclusively for in vitro laboratory research by qualified professionals.

PeptaPeptides
RETA-40
40 mg
99.0% PurityFor Research Use Only
RUO — Research Use Only
Not for human, veterinary, or clinical use
RUO
GLP-1New

RETA-40

Retatrutide 40 mg — Triple GLP-1/GIP/Glucagon Agonist

(89 reviews)
99.0% Purity
$219.99per 40 mg · lyophilized

Retatrutide is a synthetic acylated peptide engineered to simultaneously activate GLP-1, GIP, and glucagon receptors. The addition of glucagon receptor agonism to the dual incretin mechanism introduces a third complementary pathway: enhanced thermogenesis, hepatic glucose output modulation, and direct adipose tissue lipolysis via glucagon receptor activation. This triple mechanism has demonstrated particularly pronounced effects on body weight and hepatic lipid accumulation in preclinical models, making it a critical research tool for studying next-generation metabolic interventions. For research use only — not for human consumption.

3rd-Party HPLC Verified
Lot-Specific Certificate
Cold-Chain Shipping
Chemical Information
Molecular FormulaC₂₁₅H₃₃₂N₅₆O₆₄
Molecular Weight4641.20 g/mol
CAS Number2381089-83-2
FormLyophilized Powder
Storage-20°C, dry & dark
Purity (HPLC)≥ 99.0%
Amino Acid SequenceY-Aib-IGTFTSDYSIALDK(C₁₈ fatty acid)EQAAK(glucagon motif)DFIEWLQNGG
1
14 in stock
Not for Human Consumption · For Research Purposes Only
256-bit SSL
Cold-Chain Shipping
Lot-Specific CoA
ISO 9001 Facility
Independent Verification

Third-Party Tested. Every Lot.

Every batch of RETA-40 undergoes independent HPLC and mass spectrometry analysis through an accredited third-party laboratory before it is released for sale. No exceptions. No internal-only certificates.

RP-HPLC Analysis

Every lot measured by reverse-phase HPLC. RETA-40 consistently achieves 99.0%+ purity across batches.

ESI Mass Spec

Electrospray ionization mass spectrometry confirms exact molecular weight and rules out structural isomers or impurities.

Lot-Specific CoA

Your Certificate of Analysis references your exact lot number with actual chromatogram data — not a generic template.

Research Context

Theoretical Research Analysis

All research information below reflects published preclinical literature only. This product is not for human use, consumption, or clinical application of any kind.

Triple GLP-1/GIP/glucagon receptor agonism
Thermogenesis and energy expenditure research
Hepatic lipid metabolism and NAFLD models
Adipose tissue lipolysis studies
Next-generation metabolic pathway research

Retatrutide has produced some of the most dramatic preclinical weight loss data observed with any peptide to date. The glucagon receptor component appears to drive additive thermogenic and lipolytic effects beyond what GLP-1/GIP dual-agonism achieves alone.

Sequence Information

Amino acid sequence:

Y-Aib-IGTFTSDYSIALDK(C₁₈ fatty acid)EQAAK(glucagon motif)DFIEWLQNGG

Molecular Formula

C₂₁₅H₃₃₂N₅₆O₆₄

Molecular Weight

4641.20 g/mol

FDA Disclaimer: The information and statements contained on this website have not been evaluated by the United States Food and Drug Administration. The products offered by PeptaPeptides LLC and the statements made herein are not intended to diagnose, treat, cure, or prevent any disease or medical condition. PeptaPeptides LLC functions solely as a chemical supplier and raw material provider. PeptaPeptides LLC is not a compounding pharmacy, nor does it constitute a chemical compounding facility as that term is defined under Section 503A of the Federal Food, Drug, and Cosmetic Act. PeptaPeptides LLC is likewise not an outsourcing facility as defined under Section 503B of the Federal Food, Drug, and Cosmetic Act. All compounds and materials offered are provided exclusively for laboratory research, scientific analysis, and in vitro use by qualified researchers and institutions. None of the products available through PeptaPeptides LLC are intended for, approved for, or suitable for human consumption in any form.